Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | Allergy, Asthma & Clinical Immunology

Fig. 2

From: Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials

Fig. 2

Example to Illustrate the Reactive Dose. Step-up challenge dosing schedule for screening and exit DBPCFC for the PALISADE trial. Participants who were in the ARTEMIS (ARC010) trial had a maximum screening DBPCFC dose of 300 mg. Participants who tolerated doses of peanut protein had subsequently higher doses until a reactive dose was reached. The prior dose to the reactive dose was defined as the single highest tolerated dose, or maximum tolerated dose. DBPCFC double-blind, placebo-controlled food challenge

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us